Catalyst Biosciences Stock News

NEW YORK , Jan. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APM, F, NOK, CBIO, and GE. … Full story available on Benzinga.com

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for CB 4332 for the treatment of Complement Factor I (CFI) deficiency (CFID). "The granting of the Rare Pediatric Disease Designation for CB 4332 underscores the significant unmet medical need in pediatric patients with CFID. We are focused on efficiently advancing the development of CB 4332 and our complement medicines portfolio in a number of complement-driven diseases in hematology, nephrology and ophthalmology. We are pleased with the FDA''s assessment of CB 4332 as a potential therapy for underserved pediatric patients with CFID and the granting of the RPDD," said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences. Under the FDA''s rare pediatric disease designation program, the FDA may grant a priority review voucher to a sponsor who receives a product approval for a rare pediatric disease.

Catalyst Biosciences, Inc. (CBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Catalyst Biosciences Inc (CBIO) shares closed today at 0.5% above its 52 week low of $0.83, giving the company a market cap of $26M. The stock is currently down 8.5% year-to-date, down 86.5% over the past 12 months, and down 91.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 34.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -559.5% The company's stock price performance over the past 12 months lags the peer average by 507.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) with the stream of -1.42% also noticed, India Isoray, Inc. (AMEX:ISR) encountered a rapid change of -1.45% in the last hour of Tuesdays trading session. Catalyst The post Have a gripe on this: Catalyst Biosciences, Inc. (NASDAQ:CBIO), Isoray, Inc. (AMEX:ISR) appeared first on Stocks Equity .

Uber Technologies, Inc. (NYSE:UBER) with the stream of 1.53% also noticed, India Catalyst Biosciences, Inc. (NASDAQ:CBIO) encountered a rapid change of -2.93% in the last hour of Wednesdays trading session. The post Active Stock Evaluation: Uber Technologies, Inc. (NYSE:UBER), Catalyst Biosciences, Inc. (NASDAQ:CBIO) appeared first on Stocks Equity .

Catalyst Biosciences Inc (CBIO) shares closed today at 0.8% above its 52 week low of $1.24, giving the company a market cap of $39M. The stock is currently down 80.2% year-to-date, down 78.4% over the past 12 months, and down 89.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 19.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 720.7% The company's stock price performance over the past 12 months lags the peer average by 588.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29-December

Catalyst Biosciences Inc. (NASDAQ:CBIO) price on Wednesday, November 17, fall -6.49% below its previous days close as a downside momentum from buyers pushed the stocks value to $1.44. A look at the stocks price movement, the close in the last trading session was $1.54, moving within a range at $1.42 and $1.57. The beta value What Does 2021 Hold For Catalyst Biosciences Inc. (NASDAQ:CBIO)? Read More »

Catalyst Biosciences, Inc. (CBIO) with the stream of -2.40% also noticed, India Abeona Therapeutics Inc. (ABEO) encountered a rapid change of -1.77% in the last hour of Tuesdays trading session. The post Bright Stock Buzz: Catalyst Biosciences, Inc. (NASDAQ:CBIO), Abeona Therapeutics Inc. (NASDAQ:ABEO) appeared first on Stocks Equity .

In the last trading session, 1.39 million Catalyst Biosciences Inc. (NASDAQ:CBIO) shares changed hands as the companys beta touched 1.78. With the companys per share price at $1.67 changed hands at -$0.04 or -2.34% during last session, the market valuation stood at $90.05M. CBIOs last price was a discount, traded about -352.1% off its 52-week Catalyst Biosciences Inc. (NASDAQ: CBIO) : Investors Should Not Dump CBIO Stock In 2021 Read More »

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that its chief financial officer, Clinton Musil, has resigned for personal rea

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Disea

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that a fireside chat including members of its executive management team will b